ISMRC 2023 Final Programme

26 PS-03-009 Evaluation of the anti-tumor effects of artesunate on Circulating Tumor Cells (CTCs) Galatea Kallergi, Greece PS-03-010 Evaluation of cell-free miR2110 in he- patocellular carcinoma patients’ liquid biopsies Pelin Balcik Ercin, Turkey PS-03-011 In vitro biological effects of breast can- cer circulating cell free DNA on normal breast cells Ekaterini Alexiou Chatzaki, Greece PS-03-012 Targeted treatments in gastric ade- nocarcinoma circulating tumour cells: Is combination therapy the answer? Ann-Katrin Piper, Australia PS-03-013 RAI2 as novel suppressor of cancer cell dissemination to the bone marrow Thais Pereira-Veiga, Germany PS-03-014 Targeting BCAT1 is a metabolic vulnera- bility that impairs cell proliferation and aggressiveness in renal cell carcinoma Pouria Jandaghi, Canada PS-03-015 Circulating Tumor Cells in Breast Can- cer patients with Leptomeningeal Meta- stases: Detection and in vitro Expansion Laure Cayrefourcq, France PS-03-016 Epigenomic analysis reveals a specific DNA methylation program of metasta- sis-competent circulating tumor cells in colorectal cancer Angel Diaz-Lagares, Spain PS-03-017 Ultra-Sensitive Minimal Residual Di- sease (MRD) Monitoring For Cancer Patients Using SuperRCA Mutation Assays With Flow Cytometer Readout Lei Chen, Sweden PS-03-018 The feasible approach to monitor the MRD for recurrence after the radical treatment for stage III colorectal can- cer cases Koshi Mimori, Japan PS-03-019 Evaluation of treatment response in pa- ediatric leukaemia using patient specific circulating tumour DNA analysis Fani Pujol Calderón, Sweden PS-03-020 Ultrasensitive amplicon based detection of circulating tumour DNA for identifi- cation of minimal residual disease Stefan Filges, Sweden Poster Sessions – Tuesday, 2 May 2023